CECAD Microsite

Fabian Dörr´s paper “Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer” is now online!

12/18/2017

The work of Fabian Dörr and colleagues, published in Scientific Reports, indicate that SCLC displays an actionable dependence on ATR/CHK1-mediated cell cycle checkpoints.

Small cell lung cancer (SCLC) is a difficult to treat subtype of lung cancer. One of the hallmarks of SCLC is its almost uniform chemotherapy sensitivity. However, chemotherapy response is typically transient and patients frequently succumb to SCLC within a year following diagnosis. Fabian Dörr and colleagues performed a transcriptome analysis of the major human lung cancer entities and show a significant overexpression of genes involved in the DNA damage response, specifically in SCLC.

Furthermore they demonstrate that murine SCLC tumors were highly sensitive to ATR- and CHK1 inhibitors, while Kras G12D-driven murine lung adenocarcinomas were resistant against these compounds and displayed continued growth under therapy. Altogether, the data of Fabian Dörr and colleagues indicate that SCLC displays an actionable dependence on ATR/CHK1-mediated cell cycle checkpoints.